Status:
TERMINATED
Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
Lead Sponsor:
Beckley Psytech Limited
Conditions:
Short Lasting Unilateral Neuralgiform Headache Attacks
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
Brief Summary
This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
Detailed Description
The study aims to: Determine the safety and tolerability of psilocybin when administered to patients with chronic SUNHA Determine the effects of psilocybin on cognition when administered to patients...
Eligibility Criteria
Inclusion
- \* Diagnosed with chronic SUNHA
Exclusion
- \* Other comorbidities
Key Trial Info
Start Date :
August 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 22 2022
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT04905121
Start Date
August 11 2021
End Date
April 22 2022
Last Update
October 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King's College London
London, United Kingdom